FY2020 EPS Estimates for AxoGen, Inc. (AXGN) Reduced by Jefferies Group
AxoGen, Inc. (NASDAQ:AXGN) – Research analysts at Jefferies Group cut their FY2020 earnings estimates for AxoGen in a research report issued to clients and investors on Wednesday. Jefferies Group analyst R. Denhoy now anticipates that the medical equipment provider will earn $0.12 per share for the year, down from their previous estimate of $0.13. Jefferies Group currently has a “Buy” rating and a $35.00 target price on the stock. Jefferies Group also issued estimates for AxoGen’s FY2021 earnings at $0.44 EPS.
AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Wednesday, February 28th. The medical equipment provider reported ($0.07) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. The firm had revenue of $16.97 million for the quarter, compared to the consensus estimate of $16.38 million. AxoGen had a negative return on equity of 92.24% and a negative net margin of 17.29%. The company’s quarterly revenue was up 48.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.10) earnings per share.
AxoGen (AXGN) opened at $32.95 on Friday. The company has a debt-to-equity ratio of 1.93, a quick ratio of 2.95 and a current ratio of 3.55. AxoGen has a twelve month low of $9.55 and a twelve month high of $35.40.
Large investors have recently made changes to their positions in the stock. Paloma Partners Management Co purchased a new position in AxoGen during the 4th quarter valued at about $215,000. Guggenheim Capital LLC purchased a new position in AxoGen during the 4th quarter valued at about $228,000. Valeo Financial Advisors LLC purchased a new position in AxoGen during the 3rd quarter valued at about $244,000. Nationwide Fund Advisors increased its holdings in AxoGen by 5.5% during the 2nd quarter. Nationwide Fund Advisors now owns 14,874 shares of the medical equipment provider’s stock valued at $249,000 after purchasing an additional 774 shares during the period. Finally, Gotham Asset Management LLC purchased a new position in AxoGen during the 4th quarter valued at about $249,000. Institutional investors own 69.57% of the company’s stock.
In related news, Director Jamie Mark Grooms sold 21,290 shares of the business’s stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $26.22, for a total transaction of $558,223.80. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 313,397 shares of company stock worth $8,386,910. 9.33% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “FY2020 EPS Estimates for AxoGen, Inc. (AXGN) Reduced by Jefferies Group” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/fy2020-eps-estimates-for-axogen-inc-axgn-reduced-by-jefferies-group/1906477.html.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.